Learn More About This Topic: Chat with Us | Email Us
Brand Name: Faslodex®
Fulvestrant is used to treat hormone receptor-positive breast cancer in women who have experienced menopause.
Fulvestrant is an estrogen receptor antagonist. Some types of breast cancer cells depend on estrogen to grow. Fulvestrant blocks the activity of estrogen on cancer cells. This impact can stop or slow the growth of breast cancer that requires estrogen.
A liquid solution, fulvestrant is injected into a muscle in the buttocks. Usually, fulvestrant is given once a month. The dose may be given all at once, or it may be divided into two injections.
To prevent problematic interactions between fulvestrant and other drugs, be sure to tell your doctor if you are allergic to any medications, and what other medications and supplements you are currently taking. You should also inform your doctor if you have or ever had a liver tumor, liver disease, or kidney disease, if you are pregnant or planning to become pregnant, or if you are breastfeeding. Fulvestrant should not be taken during breastfeeding.
Possible side effects may include:
- Stomach pain
- Loss of appetite
- Sore throat
- Bone, joint, or back pain
- Pain, redness or swelling where medication was injected
- Swelling of hands, feet, ankles or lower legs
- Difficulty sleeping
- Numbness, tingling, or burning of the skin
Some of fulvestrant’s side effects can be serious. Call your doctor immediately if you experience any of these symptoms:
- Shortness of breath
- Chest pain
- Hives, rash, itching
- Difficulty breathing or swallowing
- Swelling of the face, throat, tongue, lips, or eyes
Please note that this is not a comprehensive list. Patients may experience additional effects not mentioned above.
At Cancer Treatment Centers of America (CTCA), your team of cancer experts will explain each of the side effects of fulvestrant with you in detail, as well as the side effects and expectations of all other medications planned as part of your individualized treatment plan.
Fulvestrant is approved by the FDA for the following:
- Treatment of estrogen receptor-positive breast cancer in postmenopausal women whose disease has spread to other parts of the body after treatment with other antiestrogens
At CTCA, our integrative approach to cancer treatment works to fight your disease on all fronts and ensures that you remain at the center of everything we do. We encourage participation from both you and your family to make certain you are comfortable with all decisions made regarding your treatment.
Learn more about our whole-patient approach to cancer treatment. Contact our Oncology Information Specialists today at 1-800-615-3055 or Chat Now.
The information provided here is for educational purposes only. In no way should it be considered as offering medical advice. Cancer Treatment Centers of America assumes no responsibility for how this material is used. Please check with a physician if you suspect you are ill. Also note that while Cancer Treatment Centers of America frequently updates its contents, medical information changes rapidly. Therefore, some information may be out of date.